Dataset Information

Differential effects, on Oncogenic Pathway Signaling, by Derivatives of the HNF4alpha Inhibitor BI6015

ABSTRACT: Gastric cancer (GC) is a highly heterogeneous disease, having few “targeted” therapeutic drugs. Previously, we demonstrated involvement of HNF4α and WNT5A, as a prognostic GC biomarker. One previously discovered HNF4α antagonist, BI6015, demonstrated potent in vitro and in vivo hepatocellular cancer models. We extensively characterized the antineoplastic activity of derivatives of BI6015, including transfer of a nitro group from a para position to the ortho- and meta-positions. Biologic activity was assessed by treatment efficacy against a panel of GC cell lines, including pathway and functional analysis. The para positioned BI6105 compound was found substantially more growth-inhibitory, and effective in downregulating numerous oncogenic signal pathways, including the embryonic cascade WNT, and suggested WNT5A as a possible therapeutic biomarker. Here, we present a strategy for identifying effective transcription factor inhibitors and their impact on specific signaling pathways, which may provide prognostic and therapeutic biomarkers.

ORGANISM(S): Homo sapiens

PROVIDER: GSE114626 | GEO | 2019/04/17

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Background Worldwide, gastric cancer is the fourth most common malignancy and the most common cancer in East Asia. Development of targeted therapies for this disease has focused on a few known oncogenes but has had limited effects. Objective To determine oncogenic mechanisms and novel therapeutic targets specific for gastric cancer by identifying commonly dys-regulated genes from the tumors of both Asian-Pacific and Caucasian patients. Design We generated transcriptomic profiles of 22 Caucasian gastric cancer tumors and their matched non-cancerous samples, and performed an integrative analysis across different gastric cancer gene expression datasets. We examined the inhibition of commonly overexpressed oncogenes and their constituent signaling pathways by RNAi and/or pharmacologic inhibition. Results We found that HNF4α upregulation was a key signaling event in gastric tumors from both Caucasian and Asian patients, and HNF4α antagonism was antineoplastic. Perturbation experiments in GC tumor cell lines and xenograft models further demonstrated that HNF4α is downregulated by AMPKα signaling and the AMPK agonist metformin; blockade of HNF4α activity resulted in cyclin downregulation, cell cycle arrest, and tumor growth inhibition. HNF4α also regulated WNT signaling through its target gene WNT5A, a potential prognostic marker of diffuse type gastric tumors. Conclusions Our results indicate that HNF4α is a targetable oncoprotein in gastric cancer, is regulated by AMPK signaling through AMPKα, and resides upstream of WNT signaling. HNF4α may regulate “metabolic switch” characteristic of a general malignant phenotype and its target WNT5A has potential prognostic values. The AMPKα-HNF4α-WNT5A signaling cascade represents a potentially targetable pathway for drug development. Integrative analysis of Caucasian and Asian-Pacific gastric tumor expression datasets (including newly generated transcriptomic profiling of 22 tumors in this study) revealed a relatively small common sets of highly overexpressed genes.

Dataset Information

Differential effects, on Oncogenic Pathway Signaling, by Derivatives of the HNF4alpha Inhibitor BI6015

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets